Physician profile
Matej Polomsky
NPI 1760643597
$20,058.89
in general payments reported to CMS, 2019-2025
23 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $387 · 2021: $2,296 · 2022: $8,107 · 2023: $6,310 · 2024: $1,576 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,850 · Food and Beverage: $3,053 · Travel and Lodging: $1,684 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,850.00 |
| Food and Beverage | $3,052.79 |
| Travel and Lodging | $1,684.26 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $16,237.53 | 2019-2025 | Argos, Hydrus Microstent, Clareon |
| Johnson & Johnson Surgical Vision, INC. | $760.53 | 2019-2025 | Tecnis Iol, Catalys System, Veritas Vision System |
| Biotissue Holdings INC. | $501.47 | 2024 | |
| Bausch & Lomb Americas INC. | $258.09 | 2022-2024 | Ic-8 Apthera Iol, Xiidra, Miebo |
| Ivantis, INC | $257.80 | 2020-2021 | |
| Rxsight INC | $252.05 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Sun Pharmaceutical Industries INC. | $233.78 | 2019-2025 | |
| Rayner Intraocular Lenses Limited | $195.84 | 2022-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Oyster Point Pharma, INC. | $177.63 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $171.31 | 2019-2022 | |
| Glaukos Corporation | $149.00 | 2019-2024 | Ce-Marked Kxla System, Idose |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $136.46 | 2019-2021 | |
| Abbvie INC. | $124.60 | 2023-2025 | |
| Amgen INC. | $124.46 | 2024 | Tepezza |
| Carl Zeiss Meditec, INC. | $120.91 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medline Industries Lp | $108.52 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $61.06 | 2024 | Xdemvy |
| Ocular Therapeutix, INC. | $59.23 | 2024-2025 | Dextenza |
| Dompe US, INC. | $34.02 | 2021 | |
| Allergan, INC. | $31.98 | 2020 | |
| Boston Scientific Corporation | $22.68 | 2025 | Wavewriter Alpha Prime 16 |
| Staar Surgical Company | $20.42 | 2019 | |
| New World Medical,INC. | $19.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matej Polomsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.